Sign In | Join Free | My spintoband.com
spintoband.com
Changsha Zhenxiang Biotechnology Co., Ltd.
Changsha Zhenxiang Biotechnology Co., Ltd. Factory Directly Supply Raw Steroid Powder, Steroid Injection, Peptides and Sarms
Home > Pharmaceutical Raw Materials >

2068-78-2 Pharmaceutical Raw Materials Antitumor Alkaloid Vincristine Sulfate

Changsha Zhenxiang Biotechnology Co., Ltd.
Trust Seal
Verified Supplier
Credit Check
Supplier Assessment
Changsha Zhenxiang Biotechnology Co., Ltd.
City: Changsha
Province/State: Hunan
Country/Region: China
Tel: 00-86-13397492710
Contact Person:
Mr ableson

2068-78-2 Pharmaceutical Raw Materials Antitumor Alkaloid Vincristine Sulfate

Place of Origin : China
Brand Name : YC
Certification : HSE, ISO 9001, USP, BP
MOQ : Negotiable
Price : Negotiable
Packaging Details : As you require
Delivery Time : 12 hours within your payment is received
Payment Terms : T/T, Western Union, Money Gram, Bitcoin
Supply Ability : 1000kg/month
Model Number : 2068-78-2
MW : 923.04
mp : 300 °C
Water Solubility : >=1 g/100 mL at 24 ºC
storage temp. : 2-8°C
CAS : 2068-78-2
MF : C46H58N4O14S
Contact Now

2068-78-2 Pharmaceutical Raw Materials Antitumor Alkaloid Vincristine Sulfate


Quick Detail

CAS2068-78-2
MFC46H58N4O14S
MW923.04
EINECS218-190-0
mp300 °C
bp273-281 °C
storage temp.2-8°C
formlyophilized powder
Water Solubility>=1 g/100 mL at 24 ºC
Chemical PropertiesCrystalline Solid

Usage An antitumor alkaloid isolated from Vinca rosea Linn. An antineoplastic.
Usage H1-antihistamine
General Description An anticancer drug. White to slightly yellow, amorphous or crystalline powder. Sensitive to light. Odorless. pH (0.1% solution) 3.5 - 4.5.
Air & Water Reactions Very hygroscopic. Water soluble.
Reactivity Profile Sensitive to hydrolysis, oxidation and heat. Incompatible with strong oxidizing agents. .
Fire Hazard Flash point data for Vincristine sulfate are not available; however, Vincristine sulfate is probably combustible.
Biological Activity Anticancer agent; microtubule disrupter. Induces apoptosis in human lymphoma cells

Synonyms: VINCRISTINE SULFATE;VINCRISTINE SULFATE, APOCYNACEAE SPECIES;VINCRISTINE SULFATE SALT;VINCRISTINE SULPHATE;VCR;VCR, LEUKOCRISTINE SULFATE;VCR SULFATE;22-oxo-vincaleukoblastinsulfate(1:1)(salt)


Product Categories: Alkaloids;API;VINCRISTINE SULPHATE;Intermediates & Fine Chemicals;Pharmaceuticals;Additional Affinity PurificationRecombinant Protein Expression and Analysis;Plant Proteomics;Protein Purification;Purification and Detection;V5;API's;Caspases/Apoptosis;Signalling;Chiral Reagents;Heterocycles;chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract;CLARINEX;Antineoplastic;Anti-cancer & immunity


Description
Pronunciation: vin-KRISS-teen
Class: Vinca alkaloid


Trade Names
Oncovin
- Solution for Injection 1 mg/mL

Pharmacology
Mode of action is unknown. In vitro, vincristine arrests mitotic division at metaphase. It reversibly binds to microtubule and spindle proteins in the S phase.


Pharmacokinetics
Absorption
Very rapidly absorbed via IV (15 to 30 min).


Distribution
More than 90% of drug is distributed from blood to tissue, where it remains tightly but not irreversibly. Penetration across the blood brain barrier is poor.


Metabolism
Triphasic serum decay following rapid IV injection.


Elimination
Terminal t ½ is 85 h (19 to 155 h). Liver is the major excretory organ. 80% of the dose appears in the feces, 10% to 20% in the urine.

Onset
15 to 30 min.


Special Populations
Hepatic Function Impairment

A 50% reduction in dose is recommended for patients having a direct serum bilirubin more than 3 mg/dL.


Indications and Usage
Adult/Pediatric

Acute lymphocytic leukemia, lymphomas, rhabdomyosarcoma, neuroblastoma, Wilms tumor.


Unlabeled Uses
Small-cell lung carcinoma, brain tumors, multiple myeloma, Kaposi sarcoma, chronic lymphocytic and myelocytic leukemias, autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura.


Contraindications
Patients with demyelinating form of Charcot-Marie-Tooth syndrome.


Dosage and Administration
Acute Lymphocytic Leukemia, Lymphomas, Rhabdomyosarcoma, Neuroblastoma, Wilms Tumor
Adult
IV 1.4 mg/m 2 weekly (typical dose, 2 mg).


Children weighing more than 10 kg (or body surface area at least 1 m 2 )
IV 1.4 to 2 mg/m 2 weekly for 3 to 8 wk. Do not exceed a max of 2 mg/dose.


Children weighing up to 10 kg (or body surface area less than 1 m 2 )
IV 0.05 mg/kg weekly initially. Titrate dose as tolerated, up to a max of 2 mg/dose. Continue therapy for 3 to 8 wk.

Adjustment in Hepatic Insufficiency
Adult
IV A 50% reduction in dose is recommended for patients having a direct serum bilirubin value more than 3 mg/dL.


Neuroblastoma, Combination Therapy
Children weighing more than 10 kg (or body surface area at least 1 m 2 )
IV Vincristine 1 mg/m 2 /day by continuous infusion over 24 h for 3 days (total dose of 3 mg/m 2 over a 3-day period).


General Advice

  • Do not dilute vincristine for routine IV use. For continuous IV infusion, vincristine may be diluted with 0.9% Sodium Chloride or 5% Dextrose.
  • Administer by IV injection or continuous IV infusion.
  • Do not filter.
  • Give over a 1-min period by IV push injection or IV side arm into a running infusion.
  • Continuous infusions can only be administered through a central venous catheter resting in the vena cava. A peripherally-inserted central catheter, or PICC line, may also be appropriate.

Storage/Stability
Refrigerate. Protect from light.


Drug Interactions
CYP-450 inhibitors

Vincristine elimination may be reduced by CYP-450 enzyme inhibitors.


Digoxin
May decrease digoxin plasma concentration.


Itraconazole
Vincristine neurotoxicity has occurred during coadministration.


L-asparaginase
Vincristine clearance may decrease when L-asparaginase is given prior to vincristine. Give vincristine 12 to 24 hr prior to L-asparaginase.


Mitomycin
Acute shortness of breath and severe bronchospasm have occurred following concomitant or previous use of mitomycin.


Phenytoin
May reduce phenytoin plasma concentration.


Quinolone antibiotics
Vincristine may decrease oral absorption of quinolone antibiotics.


Laboratory Test Interactions
None well documented.


Adverse Reactions

Cardiovascular
Hypertension; hypotension; MI.


CNS
Autonomic and peripheral neuropathy; headache.


Dermatologic
Alopecia; rash


GI
Mucositis; abdominal cramps; diarrhea; anorexia; intestinal necrosis or perforation; constipation that can lead to upper colon impaction; paralytic ileus; weight loss.


Genitourinary
Amenorrhea; polyuria; dysuria; urinary retention because of bladder atony; azoospermia.


Hematologic
Bone marrow suppression; nadir less than 7 days.


Musculoskeletal
Acute bone or jaw pain.


Respiratory
Acute shortness of breath; severe bronchospasm.


Special Senses
Optic atrophy with blindness; transient cortical blindness; ptosis; diplopia; photophobia.


Miscellaneous
Fever.


Product Tags:

active pharmaceutical intermediates

      

pharma steroids

      
China Customized Inflatable Bumper Ball Game Bubble Adult Grass CE supplier

2068-78-2 Pharmaceutical Raw Materials Antitumor Alkaloid Vincristine Sulfate Images

Inquiry Cart 0
Send your message to this supplier
 
From:
Enter your email please.
To: Changsha Zhenxiang Biotechnology Co., Ltd.
Subject:
Message:
Characters Remaining: (0/3000)
 
Inquiry Cart 0